The company's paediatric phase 3 PARADIGMS study met its primary endpoint, showing a significant reduction in relapses in patients treated with Gilenya (fingolimod) versus Biogen’s Avonex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback